Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -44.14M | -35.19M | -25.72M | -28.77M | -7.87M |
| Total Depreciation and Amortization | 741.00K | 1.07M | 1.17M | 1.25M | 1.37M |
| Total Amortization of Deferred Charges | 10.71M | 9.81M | 7.20M | 4.59M | 1.97M |
| Total Other Non-Cash Items | 6.88M | 6.44M | 5.62M | 5.02M | 3.49M |
| Change in Net Operating Assets | -9.96M | -16.34M | -12.95M | -7.67M | -5.34M |
| Cash from Operations | -35.76M | -34.21M | -24.68M | -25.58M | -6.38M |
| Capital Expenditure | -159.00K | -160.00K | -231.00K | -1.02M | -995.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -159.00K | -160.00K | -231.00K | -1.02M | -995.00K |
| Total Debt Issued | -- | 31.14M | 31.14M | 31.14M | 31.14M |
| Total Debt Repaid | -23.00K | -39.00M | -39.00M | -42.45M | -51.53M |
| Issuance of Common Stock | 84.72M | 88.17M | 92.96M | 98.98M | 17.26M |
| Repurchase of Common Stock | -1.10M | -1.10M | -898.00K | -896.00K | -11.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.00K | 8.14M | 8.14M | 8.14M | 7.11M |
| Cash from Financing | 83.59M | 87.35M | 92.34M | 94.92M | 3.97M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.67M | 52.98M | 67.43M | 68.32M | -3.40M |